POINT Biopharma Global Inc.
NASDAQ:PNT
12.5 (USD) • At close December 26, 2023
Overzicht | Financiële gegevens
Bedrijfsnaam | POINT Biopharma Global Inc. |
Symbool | PNT |
Munteenheid | USD |
Prijs | 12.5 |
Beurswaarde | 1,332,112,500 |
Dividendpercentage | 0% |
52-weken bereik | 6.57 - 14.35 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Joe A. McCann Ph.D. |
Website | https://www.pointbiopharma.com |
An error occurred while fetching data.
Over POINT Biopharma Global Inc.
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand,
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)